- Report
- November 2024
- 716 Pages
Global
From €4368EUR$4,799USD£3,744GBP
- Report
- October 2024
- 1300 Pages
Global
From €3549EUR$3,900USD£3,043GBP
- Report
- February 2025
Global
From €4459EUR$4,900USD£3,823GBP
- Report
- October 2024
- 181 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- December 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- April 2025
- 193 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- March 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- July 2024
- 303 Pages
Global
From €3185EUR$3,500USD£2,731GBP
€4551EUR$5,000USD£3,901GBP
- Report
- March 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,784GBP
- Report
- March 2025
- 450 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- January 2022
- 132 Pages
Global
From €4368EUR$4,799USD£3,744GBP
- Report
- February 2024
- 468 Pages
Global
From €4368EUR$4,799USD£3,744GBP
- Report
- November 2022
- 154 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- September 2021
- 258 Pages
Global
From €2503EUR$2,750USD£2,146GBP
€5006EUR$5,500USD£4,291GBP
- Report
- February 2022
- 360 Pages
United States
From €3276EUR$3,600USD£2,809GBP
- Report
- March 2021
- 240 Pages
United States
From €2730EUR$3,000USD£2,341GBP
- Report
- July 2020
- 1200 Pages
Japan
From €2730EUR$3,000USD£2,341GBP
- Clinical Trials
- February 2018
- 225 Pages
Global
From €2184EUR$2,400USD£1,873GBP
- Report
- October 2023
- 273 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- April 2024
- 125 Pages
Global
From €5415EUR$5,950USD£4,642GBP

Kadcyla is an oncology drug used to treat certain types of breast cancer. It is a targeted therapy that works by blocking the HER2 protein, which is found in some types of breast cancer cells. Kadcyla is administered intravenously and is used in combination with other treatments such as chemotherapy and radiation. It is approved for use in the United States, Europe, and other countries.
Kadcyla is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials for its potential to treat other types of cancer, such as ovarian and lung cancer. The drug is also being studied for its potential to reduce the risk of recurrence in patients who have already been treated for breast cancer.
The Kadcyla market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as Roche, Novartis, and Pfizer are all involved in the development and marketing of Kadcyla. Other companies such as Merck, AstraZeneca, and Eli Lilly are also involved in the development and marketing of the drug. Show Less Read more